Tysabri and Progressive Multifocal Leukoencephalopathy: Symptoms, Timing, and Medical Documentation

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Education to Occupational and Legal Awareness

If you or a loved one is taking Tysabri (natalizumab) for multiple sclerosis or Crohn's disease, understanding the early symptoms of progressive multifocal leukoencephalopathy (PML) and the importance of timely medical documentation is critical. The medical and scientific community has long recognized that prompt diagnosis and thorough record-keeping are essential for managing this rare but serious brain infection. This page provides an objective overview of PML symptoms, risk factors, and the recommended monitoring schedule, with a focus on the prescribing information relevant to Florida patients.

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, and three known risk factors have been identified in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation and Diagnosis of PML

The clinical presentation of PML can be insidious, with symptoms that may include progressive weakness, visual disturbances, cognitive decline, and coordination difficulties. In the FDA Adverse Event Reporting System (FAERS), adverse events most frequently associated with Tysabri include fatigue, multiple sclerosis relapse, headache, gait disturbance, fall, memory impairment, asthenia, balance disorder, hypoesthesia, muscular weakness, cognitive disorder, and mobility decreased (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). These symptoms can overlap with those of multiple sclerosis itself, making early diagnosis of PML challenging. Diagnosis typically requires brain MRI and detection of JCV DNA in cerebrospinal fluid. The mechanistic pathway linking Tysabri to PML involves the drug's inhibition of alpha-4 integrin, which prevents lymphocyte trafficking into the central nervous system. This reduced immune surveillance allows reactivation of latent JCV in the brain, leading to lytic infection of oligodendrocytes and subsequent demyelination.

Statute of Limitations for Tysabri Claims in Florida

For patients in Florida who have developed PML after Tysabri exposure, legal considerations include the statute of limitations for filing a product liability claim. In Florida, the statute of limitations for personal injury actions is generally four years from the date the injury was discovered or should have been discovered with reasonable diligence. For wrongful death claims, the period is two years from the date of death. Given that PML can develop months to years after starting Tysabri, and that symptoms may be initially attributed to multiple sclerosis, the discovery date may be later than the actual onset of PML. Patients and their families should consult with an attorney promptly to determine the applicable deadline, as failure to file within the statutory period can bar recovery. The adequacy of warnings regarding Tysabri and PML is a central issue in potential litigation. The prescribing information includes a boxed warning that clearly states the increased risk of PML and identifies known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may arise about whether healthcare providers and patients were adequately informed about the magnitude of risk, the need for vigilant monitoring, and the limitations of risk stratification. The TOUCH program is designed to ensure that patients are counseled about PML risk, but program compliance and the quality of risk communication may vary. For patients who developed PML despite adherence to monitoring protocols, the issue may be whether the warnings were sufficient to allow informed decision-making.

Timeline of Exposure and Harm: Medical and Legal Implications

The timeline between Tysabri exposure and documented harm is critical for both medical and legal purposes. PML risk increases with longer treatment duration, particularly beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who have received Tysabri for extended periods, or who have additional risk factors such as prior immunosuppressant use or positive anti-JCV antibody status, are at higher risk. The latency period from JCV reactivation to clinical PML can be weeks to months, and early symptoms may be subtle. Once PML is diagnosed, the prognosis is poor, with most patients experiencing severe disability or death. For legal purposes, the date of diagnosis or the date when symptoms first became clearly attributable to PML may serve as the trigger for the statute of limitations. In summary, Tysabri-associated PML is a serious and often devastating adverse event with well-documented risk factors. Patients in Florida who have been harmed should be aware of the statute of limitations and seek legal counsel to evaluate their claims. The adequacy of warnings and the timeline of exposure and harm are key factual issues that will be examined in any product liability action.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Florida?

In Florida, the statute of limitations for personal injury claims is generally four years from the date the injury was discovered or should have been discovered. For wrongful death claims, the period is two years from the date of death. Because PML symptoms may be initially mistaken for multiple sclerosis, the discovery date may be later than the actual onset. It is crucial to consult an attorney promptly to determine the applicable deadline.

What are the known risk factors for developing PML while on Tysabri?

Three known risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients with these risk factors should be monitored closely for any signs of PML.

How is PML diagnosed in patients taking Tysabri?

Diagnosis typically requires brain MRI and detection of JCV DNA in cerebrospinal fluid. Symptoms such as progressive weakness, visual disturbances, cognitive decline, and coordination difficulties may prompt evaluation. Because these symptoms can overlap with multiple sclerosis, early diagnosis is challenging.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.